Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Asset Writedowns and Impairment: 2016-2025

Historic Asset Writedowns and Impairment for Aytu Biopharma (AYTU) over the last 9 years, with Jun 2025 value amounting to $8.3 million.

  • Aytu Biopharma's Asset Writedowns and Impairment rose 200.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 522.76%. This contributed to the annual value of $8.3 million for FY2025, which is 588.58% up from last year.
  • Per Aytu Biopharma's latest filing, its Asset Writedowns and Impairment stood at $8.3 million for FY2025, which was up 588.58% from $1.2 million recorded in FY2024.
  • Aytu Biopharma's 5-year Asset Writedowns and Impairment high stood at $75.5 million for FY2022, and its period low was $1.2 million during FY2024.
  • For the 3-year period, Aytu Biopharma's Asset Writedowns and Impairment averaged around $5.1 million, with its median value being $5.7 million (2023).
  • In the last 5 years, Aytu Biopharma's Asset Writedowns and Impairment soared by 886.54% in 2021 and then tumbled by 92.44% in 2023.
  • Yearly analysis of 5 years shows Aytu Biopharma's Asset Writedowns and Impairment stood at $12.8 million in 2021, then skyrocketed by 488.37% to $75.5 million in 2022, then tumbled by 92.44% to $5.7 million in 2023, then slumped by 78.97% to $1.2 million in 2024, then skyrocketed by 588.58% to $8.3 million in 2025.